Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Molecular Templates, Inc. (MTEM)

0.4953   0 (0%) 12-05 16:00
Open: 0.5417 Pre. Close: 0.4953
High: 0.5417 Low: 0.4953
Volume: 167 Market Cap: 28(M)

Technical analysis

as of: 2022-12-06 9:49:42 AM
Overall:       
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 0.7     One year: 0.79
Support: Support1: 0.47    Support2: 0.39
Resistance: Resistance1: 0.6    Resistance2: 0.68
Pivot: 0.57
Moving Average: MA(5): 0.51     MA(20): 0.57
MA(100): 0.72     MA(250): 1.66
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 19.7     %D(3): 24.2
RSI: RSI(14): 37.9
52-week: High: 4.44  Low: 0.47
Average Vol(K): 3-Month: 121 (K)  10-Days: 251 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ MTEM ] has closed above bottom band by 5.9%. Bollinger Bands are 9.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.54 - 0.54 0.54 - 0.55
Low: 0.5 - 0.5 0.5 - 0.5
Close: 0.5 - 0.51 0.51 - 0.51

Company Description

Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases. The company primarily develops a pipeline of therapies through its proprietary biologic engineered toxin body (ETB) drug platform. The company is developing MT-5111, an ETB candidate that is in Phase I clinical trial for the treatment of HER2-positive cancers; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory myeloma patients; and MT-6402 in that is in Phase I clinical trial for PD-1/PD-L1 antibody relapsed/refractory patients. Its pipeline of ETBs in development for other targets, including CTLA-4, TIGIT, TROP2, BCMA, SLAMF-7, and CD45. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.

Headline News

Fri, 02 Dec 2022
Molecular Templates, Inc. to Present Interim Results on MT-5111 at the 45th Annual San Antonio Breast Cancer Symposium (SABCS) and Participate at the 64th American Society of Hematology (ASH) Annual Meeting - Marketscreener.com

Fri, 02 Dec 2022
MOLECULAR TEMPLATES, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K) - Marketscreener.com

Wed, 23 Nov 2022
Molecular Templates, Inc. to Present Fireside Chats at Two Upcoming Investor Conferences: Evercore ISI’s 5th Annual HealthCONx Conference and Piper Sandler’s 34th Annual Healthcare Conference - Yahoo Finance

Wed, 16 Nov 2022
What Does The Future Hold For Molecular Templates, Inc. (NASDAQ:MTEM)? These Analysts Have Been Cutting Their Estimates - Simply Wall St

Thu, 10 Nov 2022
Acutus Medical, Inc. (AFIB) Reports Q3 Loss, Tops Revenue Estimates - Nasdaq

Thu, 10 Nov 2022
Molecular Templates, Inc. Reports Third Quarter 2022 Financial Results - Yahoo Finance

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Neutral
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Outperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 56 (M)
Shares Float 38 (M)
% Held by Insiders 4.8 (%)
% Held by Institutions 74.6 (%)
Shares Short 533 (K)
Shares Short P.Month 492 (K)

Stock Financials

EPS -1.39
EPS Est Next Qtl 0
EPS Est This Year -0.75
EPS Est Next Year -0.78
Book Value (p.s.) 0.07
Profit Margin (%) -230.5
Operating Margin (%) -218
Return on Assets (ttm) -28.5
Return on Equity (ttm) -212.3
Qtrly Rev. Growth 78.1
Gross Profit (p.s.) -0.82
Sales Per Share 0.62
EBITDA (p.s.) -1.23
Qtrly Earnings Growth 0
Operating Cash Flow -93 (M)
Levered Free Cash Flow -29 (M)

Stock Valuations

PE Ratio -0.36
PEG Ratio -0.2
Price to Book value 7.07
Price to Sales 0.79
Price to Cash Flow -0.3

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date 2017-08-01
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.